Bixiye
QP6-21 MHCP Pharmacy Benefit Exclusion for OxlumoTM and Danyelza®
Taariikhda uu dhaqangalayo Barnaamijka: Jan 27, 2021
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2351 - 2360 ee natiijooyinka 3289
Bixiye
QP8-21 Change in Suspect COVID-19 Diagnosis Code
Taariikhda uu dhaqangalayo Barnaamijka: Jan 27, 2021
Bixiye
QP4-21 Commercial Pharmacy Benefit Exclusion for OxlumoTM
Taariikhda uu dhaqangalayo Barnaamijka: Jan 27, 2021
Bixiye
QP1-21 Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective March 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: Jan 13, 2021
Bixiye
QP3-21 Commercial and MHCP Pharmacy Benefit Exclusion for Barhemsys® and Monoferric®
Taariikhda uu dhaqangalayo Barnaamijka: Jan 13, 2021
Bixiye
QP2-21 Update for New to Market Medical Drugs: Aducanumab, Casimersen, Evinacumab, Idecabtagene Vicleucel, and Pegunigalsidase Alfa
Taariikhda uu dhaqangalayo Barnaamijka: Jan 13, 2021
Bixiye
P81R1-20 Update: eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Jan 04, 2021
Bixiye
P5-21 New Reimbursement Policy: Outpatient Services Prior to an Inpatient Admission
Taariikhda uu dhaqangalayo Barnaamijka: Jan 04, 2021
Bixiye
P1-21 Retro Reviews for Post-Acute Care and Home Health Prior Authorizations
Taariikhda uu dhaqangalayo Barnaamijka: Jan 04, 2021
Bixiye
2021 January Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: Jan 04, 2021